Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) CFO Eyal Desheh remains upbeat about Teva’s attempts to buy Mylan N.V. (Nasdaq: MYL). At the same time, Mylan continues to oppose the takeover bid and believes that it is about to receive US Food and Drug Administration (FDA) approval to market a generic version of Copaxone, Teva’s flagship branded drug for treating multiple sclerosis.
Mylan CEO Heather Bresch and CFO John Sheehan took part yesterday in the Bank of America Merrill Lynch Health Care Conference and analyst Suman Kulkarni published presentations of Mylan and Teva afterwards. On Mylan he wrote, “On generic Copaxone, MYL stated that it went through the FDA’s response to TEVA’s eight citizen petitions and believes that its generic Copaxone meets all the criteria from a scientific perspective. MYL continues to expect approval at any time.”… [READ MORE]
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
Published by Globes [online], Israel business news – www.globes-online.com –